207 related articles for article (PubMed ID: 24376829)
1. Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions.
Deja S; Dawiskiba T; Balcerzak W; Orczyk-Pawiłowicz M; Głód M; Pawełka D; Młynarz P
PLoS One; 2013; 8(12):e84637. PubMed ID: 24376829
[TBL] [Abstract][Full Text] [Related]
2. Metabolite signature of human malignant thyroid tissue: A systematic review and meta-analysis.
Razavi SA; Khorsand B; Salehipour P; Hedayati M
Cancer Med; 2024 Apr; 13(8):e7184. PubMed ID: 38646957
[TBL] [Abstract][Full Text] [Related]
3. Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study.
Torregrossa L; Shintu L; Nambiath Chandran J; Tintaru A; Ugolini C; Magalhães A; Basolo F; Miccoli P; Caldarelli S
J Proteome Res; 2012 Jun; 11(6):3317-25. PubMed ID: 22509853
[TBL] [Abstract][Full Text] [Related]
4. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of post-surgical fine-needle aspiration biopsies of thyroid lesions with indeterminate cytology using HRMAS NMR-based metabolomics.
Rezig L; Servadio A; Torregrossa L; Miccoli P; Basolo F; Shintu L; Caldarelli S
Metabolomics; 2018 Oct; 14(10):141. PubMed ID: 30830426
[TBL] [Abstract][Full Text] [Related]
6. Can CD10 be used as a diagnostic marker in thyroid pathology?
Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
[TBL] [Abstract][Full Text] [Related]
8. [Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules].
Wang LH; Zhao YJ; Wang XY; Yuan P; Xu WQ; Xiao JC; Xu JP; Luo BR
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):547-50. PubMed ID: 16438854
[TBL] [Abstract][Full Text] [Related]
9. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents.
Zhou Q; Zhang LY; Xie C; Zhang ML; Wang YJ; Liu GH
Pediatr Surg Int; 2020 Feb; 36(2):145-153. PubMed ID: 31576470
[TBL] [Abstract][Full Text] [Related]
11. Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms.
De Nicola H; Szejnfeld J; Logullo AF; Wolosker AM; Souza LR; Chiferi V
J Ultrasound Med; 2005 Jul; 24(7):897-904. PubMed ID: 15972703
[TBL] [Abstract][Full Text] [Related]
12. The metabolomics and lipidomics window into thyroid cancer research.
Farrokhi Yekta R; Rezaie Tavirani M; Arefi Oskouie A; Mohajeri-Tehrani MR; Soroush AR
Biomarkers; 2017 Nov; 22(7):595-603. PubMed ID: 27805426
[TBL] [Abstract][Full Text] [Related]
13. Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant neoplasms.
Russell P; Lean CL; Delbridge L; May GL; Dowd S; Mountford CE
Am J Med; 1994 Apr; 96(4):383-8. PubMed ID: 8166160
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
15. Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation.
Abooshahab R; Gholami M; Sanoie M; Azizi F; Hedayati M
Endocrine; 2019 Jul; 65(1):1-14. PubMed ID: 30937722
[TBL] [Abstract][Full Text] [Related]
16. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
18. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
19. An antibody-like peptide that recognizes malignancy among thyroid nodules.
Reis CF; Carneiro AP; Vieira CU; Fujimura PT; Morari EC; Silva SJ; Goulart LR; Ward LS
Cancer Lett; 2013 Jul; 335(2):306-13. PubMed ID: 23462224
[TBL] [Abstract][Full Text] [Related]
20. Spectroscopic identification of benign (follicular adenoma) and cancerous lesions (follicular thyroid carcinoma) in thyroid tissues.
Depciuch J; Stanek-Widera A; Skrzypiec D; Lange D; Biskup-Frużyńska M; Kiper K; Stanek-Tarkowska J; Kula M; Cebulski J
J Pharm Biomed Anal; 2019 Jun; 170():321-326. PubMed ID: 30954022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
